Summary：**Getinge's Q2 2026 Report Delivers Impressive Growth, Profitability, and Cash Flow** *Introduction

**Getinge's Q2 2026 Report Delivers Impressive Growth, Profitability, and Cash Flow**

*Introduction*
Getinge AB unveiled its second‑quarter 2026 results on Thursday, posting figures that surpassed analyst expectations across revenue, earnings, and liquidity. The Swedish medical‑technology group reported a 12.4 % year‑on‑year increase in net sales, driven by strong demand for its intensive‑care and life‑science solutions. Adjusted EBITDA rose to SEK 2.1 billion, while free cash flow climbed to SEK 1.8 billion, underscoring a turnaround in operational efficiency that investors have been watching closely since the start of the year.

*Key Developments*
Revenue growth was anchored by two core divisions. The Critical Care segment saw a 15 % surge, propelled by upgraded ventilator platforms and expanded service contracts in North America and Europe. Meanwhile, the Life Sciences unit posted a 9 % rise, fueled by higher sales of sterilization equipment and bioprocessing systems to pharmaceutical manufacturers. On the profitability front, Getinge’s gross margin improved to 38.2 % from 35.6 % a year earlier, reflecting cost‑saving initiatives and a favorable product mix. Cash conversion strengthened, with operating cash flow representing 86 % of adjusted EBITDA, a notable improvement from the 72 % recorded in Q2 2025.

*Industry Analysis*
The broader med‑tech landscape continues to navigate post‑pandemic normalization, yet demand for advanced critical‑care infrastructure remains robust, especially as hospitals invest in resilient supply chains and digital integration. Getinge’s performance aligns with a sector trend where companies that combine hardware innovation with recurring service revenues outperform pure‑play equipment sellers. Analysts note that Getinge’s focus on aftermarket sales—now accounting for